# Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02105974** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1621 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Furoate/Vilanterol
- **DRUG:** Vilanterol

## Key facts

- **NCT ID:** NCT02105974
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2015-07-08
- **Final completion:** 2015-07-08
- **Target enrollment:** 1621 (ACTUAL)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02105974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02105974, "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02105974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*